As shared on drugs.com, Vascarta Inc. has reported encouraging results from a Phase 1b clinical study evaluating its investigational topical/transdermal curcumin gel, VAS-101, for the treatment of knee pain associated…
As reported on drugs.com, Revolution Medicines has reported practice-changing efficacy results from a pivotal Phase 3 trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), one of the…
As reported on Business Wire, Enveda, a clinical-stage biotechnology company focused on discovering novel small-molecule medicines, has reported encouraging results from a Phase 1b study evaluating its investigational therapy ENV-294…
Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults and remains one of the most difficult cancers to treat. Characterized by aggressive growth and diffuse microscopic spread,…
As reported by Business Wire, Enanta Pharmaceuticals has initiated its first clinical study of EDP-978, a novel oral inhibitor of the KIT receptor tyrosine kinase being developed for chronic urticaria…
As reported on PharmaBiz, ModeX Therapeutics, a clinical-stage biotechnology company within OPKO Health, has begun dosing patients in a first-in-human clinical trial evaluating MDX2003, a next-generation tetra-specific T‑cell engager for…
As reported on Business Wire, Motif Neurotech has received clearance from the U.S. Food and Drug Administration (FDA) to initiate its first clinical study evaluating an implantable brain–computer interface (BCI)…
Early Phase III data suggest C5 complement inhibition may alter disease course in IgAN In a recent press release, AstraZeneca reported that Ultomiris (ravulizumab) has shown a statistically significant and…
As reported on NBC News, an ophthalmologist with a history of criticizing the U.S. government’s Covid-19 vaccine strategy is emerging as a leading contender to oversee the Food and Drug…
As reported on PharmaBiz, Roche has secured CE mark approval for its Elecsys Neurofilament Light Chain (NfL) assay, a blood-based test designed to help detect neuroinflammation in adults with relapsing-remitting…
As reported on BioPharmaDive, Roche is restarting efforts to get Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD), approved in Europe by launching a new global Phase 3 trial…
As reported on Healthline, a man in Norway has entered sustained HIV remission following a stem cell transplant, becoming one of a small number of individuals worldwide to achieve what…
As reported on Cardiovascular Business, new long-term findings presented at the American College of Cardiology (ACC) 2026 meeting provide compelling evidence that early and continuous treatment with acoramidis (Attruby) confers…
As reported by Manila Times, Ocular Therapeutix has released additional one‑year results from its Phase 3 SOL‑1 trial evaluating AXPAXLI (formerly OTX‑TKI) for the treatment of neovascular age‑related macular degeneration…
As reported on BioPharmaDive, several biopharmaceutical companies reported notable clinical and regulatory developments this week, with investor response reflecting growing confidence in both late‑stage pipelines and lifecycle management strategies. United…
Akebia Therapeutics has initiated clinical development of a new investigational therapy aimed at preventing or treating acute kidney injury (AKI) associated with cardiac surgery. The company announced that the first…
Phase 2 data suggest meaningful skin improvement and an acceptable safety profile As reported on Healio, litifilimab, an investigational therapy developed by Biogen, demonstrated encouraging efficacy and tolerability in patients…
As reported on PharmaBiz, Amgen has announced encouraging topline results from a phase 3 clinical trial evaluating a subcutaneous formulation of Tepezza (teprotumumab-trbw) for adults with moderate-to-severe active thyroid eye…
As reported by GlobeNewsWire, results from the Phase 3 VALOR trial evaluating brepocitinib in adults with dermatomyositis have been published in the New England Journal of Medicine, marking a significant…
As reported on PharmaBiz, a novel treatment strategy combining dual immunotherapy, targeted therapy, and transarterial chemoembolization (TACE) has demonstrated meaningful clinical benefit for patients with unresectable hepatocellular carcinoma (HCC), according…
As reported on BioPharmaDive, Amgen has announced positive Phase 3 results for a subcutaneous version of its thyroid eye disease (TED) therapy Tepezza, suggesting the new formulation performs similarly to…
As reported on Business Wire, Alkermes plc has initiated a global phase 3 clinical development program to evaluate alixorexton, an investigational oral therapy for people living with narcolepsy type 1…
As reported on FierceBioTech, Gilead Sciences has closed one of its midstage clinical studies evaluating an experimental HIV regimen, following ongoing safety concerns that prompted U.S. regulators to intervene last…
As reported on PharmaBiz, the US Food and Drug Administration (FDA) has approved Novo Nordisk’s higher‑dose formulation of semaglutide, Wegovy HD (7.2 mg once weekly), for chronic weight management. The…
As reported on PharmaBiz, Illumina and Labcorp have announced an expanded strategic collaboration aimed at accelerating precision oncology by applying next-generation sequencing (NGS) technologies more broadly across cancer care. The…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
